NCT04893148 is a Phase 4 clinical trial of IGlarLixi in Type 2 Diabetes Mellitus, sponsored by Chungbuk National University Hospital.

Who is sponsoring NCT04893148?

NCT04893148 is sponsored by Chungbuk National University Hospital.

What drugs are being tested in NCT04893148?

Interventions in NCT04893148: IGlarLixi, Dulaglutide.

What condition does NCT04893148 study?

NCT04893148 studies Type 2 Diabetes Mellitus, Glucose, High Blood.

Is NCT04893148 still recruiting?

NCT04893148 is currently status unknown. Last updated 20 July 2022.

Last reviewed 2022-07-20 · How we verify

NCT04893148

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

Status unknown Phase 4 Last updated 20 July 2022

What this trial tests

Phase 4 trial testing IGlarLixi in Type 2 Diabetes Mellitus in 40 participants. Status unknown.

Timeline

26 May 2020

Primary endpoint
30 December 2021

30 December 2022

Quick facts

Lead sponsor	Chungbuk National University Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	26 May 2020
Primary completion	30 December 2021
Estimated completion	30 December 2022
Sites	1 location across South Korea

Drugs / interventions tested

IGlarLixi — full drug profile →
Dulaglutide (DULAGLUTIDE) — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Glucose, High Blood — all drugs for Glucose, High Blood →

Sponsor

Chungbuk National University Hospital

Who can join

18 and older, any sex, with Type 2 Diabetes Mellitus or Glucose, High Blood. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aimed to compare efficacy and safety of IGlarLixi and insulin glargine plus dulaglutide as intensification from basal insulin with metformin, in the absence of head-to-head trials.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of IGlarLixi

Trials testing the same drug.

NCT04196231 — Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen · Phase 4 · completed
NCT03881995 — Effects of Insulin Glargine and Lixisenatide on the Brain · Phase 4 · terminated

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Chungbuk National University Hospital trials

Trials by the same sponsor.

NCT07037303 — Comparing Active Cycle of Breathing Techniques (ACBT) and Aerobika in Treating Bronchiectasis in Korea · NA · not yet recruiting
NCT05994547 — Efficacy and Safety of Remimazolam Compared With Midazolam During Bronchoscopy:Randomised Controlled Trial · Phase 4 · completed
NCT04552574 — Randomized Clinical Trial of HMR(Home Meal Replacement)-Type Omega-3-balanced-diet · NA · unknown
NCT04647838 — Tepotinib in Solid Tumors Harboring MET Alterations · Phase 2 · unknown
NCT03473262 — Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04893148 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chungbuk National University Hospital
Last refreshed: 20 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04893148.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing